Notably, the transcriptional regulation of Fpn by Hif2α has also been well described,[20, 22, 29] these important findings have created new therapeutic opportunities for the treatment of hemochromatosis and anemia. This evidence concerns the gene EPAS1 and hemochromatosis type 1.